Form 4: Plus Therapeutics CEO Reports Stock Transactions

Marc Hedrick, CEO of Plus Therapeutics, reported transactions involving restricted stock units and stock options on May 14, 2026.

Summary

• Marc Hedrick, Chief Executive Officer and Director of Plus Therapeutics, Inc. (PSTV), reported a transaction on May 14, 2026.
• The transaction involved the acquisition of 23,834 Restricted Stock Units (RSUs) with a reported value of $0.
• Additionally, 23,834 stock options with an exercise price of $5.76 were acquired on the same date.
• These RSUs vest ratably over twelve quarters, with the first vesting on July 1, 2026.
• The stock options vest over four years on a monthly basis and also vest upon a change of control.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral filing, as it represents standard executive compensation and stock grant activity rather than a significant strategic or financial event.

Positives

• The CEO's acquisition of RSUs and stock options indicates a continued investment and commitment to the company's future.
• The vesting schedule for RSUs and options aligns with long-term performance and retention goals.

Negatives

• The reported value of the RSUs at the time of acquisition was $0, which is a standard accounting treatment but may be perceived negatively if not understood.

Risks

• The vesting of stock options is contingent on continued employment and may be accelerated upon a change of control, introducing potential risk related to corporate events.
• The value of the stock options is directly tied to the future stock price performance of Plus Therapeutics.

Future Outlook

The future outlook for the acquired RSUs and stock options is tied to the company's performance and stock price, with specific vesting dates and an expiration date for the options.

Industry Context

StockSavvy.ai notes that insider transactions, such as the acquisition of stock options and RSUs by executives, are common in the biotechnology and pharmaceutical sectors as a means of aligning executive interests with shareholder value and incentivizing long-term growth.

Stakeholder Impact

• Shareholders: The acquisition of stock by the CEO through options and RSUs can be viewed positively as it aligns executive interests with long-term shareholder value.
• Employees: The vesting schedules for these awards are standard and do not directly impact other employees but reflect the company's compensation philosophy.
• Management: The CEO's continued stake and incentive through these awards reinforce their commitment to the company's success.

Next Steps

• Vesting of Restricted Stock Units over twelve quarters commencing July 1, 2026.
• Vesting of stock options over four years on a monthly anniversary basis.
• Potential vesting of stock options upon a change of control.

Key Dates

Keywords

Plus Therapeutics, PSTV, Form 4, SEC Filing, Stock Options, Restricted Stock Units, Insider Trading, Executive Compensation, Marc Hedrick